Safety and Efficacy of CDCA in CTX Chenodeoxycholic Acid (CDCA) in Patients Affected by Cerebrotendinous Xanthomatosis (CTX)

NCT05499026 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 28

Last updated 2022-08-12

No results posted yet for this study

Summary

Retrospective study of CTX patients to investigate the safety and clinical efficacy of Chenodeoxycholic Acid

Conditions

  • Cerebrotendinous Xanthomatoses

Interventions

DRUG

Chenodeoxycholic Acid

Bile acid

Sponsors & Collaborators

  • Leadiant Biosciences Ltd.

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-09
Primary Completion
2015-06-03
Completion
2015-06-03

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05499026 on ClinicalTrials.gov